Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells

Oncogene

Volumn 28, Issue 11, 2009, Pages 1421-1431

  Finkbeiner, M R ^a   Astanehe, A ^a   To, K ^a   Fotovati, A ^a   Davies, A H ^a   Zhao, Y ^a   Jiang, H ^a   Stratford, A L ^a   Shadeo, A ^b   Boccaccio, C ^c   Comoglio, P ^c   Mertens, P R ^d   Eirew, P ^e   Raouf, A ^e   Eaves, C J ^e   Dunn, S E ^a,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Basallike breast cancer; ChIP on chip; Mammary progenitors; MET receptor; YB 1

Indexed keywords

SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CD44 GENE; CD49F GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MET GENE; MULTIGENE FAMILY; NOTCH GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION; WILD TYPE; WNT GENE; YB 1 GENE;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HEPATOCYTE GROWTH FACTOR; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; RNA, SMALL INTERFERING; STEM CELLS;

EID: 62649165025     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.485     Document Type: Article

References (37)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Nat Acad Sci USA 100: 3983-3988.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
3. Boccaccio C, Comoglio PM. (2006). Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637-645.
4. Boon EMJ, van der Neut R, van de Wetering M, Clevers H, Pals ST. (2002). Wnt signaling regulates the receptor tyrosine kinase Met in colorectal cancer. Cancer Res 62: 5126-5128.
5. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N et al. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284.
6. Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. (2007). Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12: 253-270.
7. Comoglio PM, Giordano S, Trusolino L. (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516.
8. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. (2004). Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6: R605-R615.
9. Dunn BK, Ford LG. (2007). Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prev 16: 232-242.
10. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT et al. (2008). A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 14: 1384-1389. Published online, 23 November.
11. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG et al. (2007). Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 99: 616-627.
12. Gambarotta G, Boccaccio C, Giordano S, Ando M, Stella MC, Comoglio PM. (1996). Ets up-regulates MET transcription. Oncogene 13: 1911-1917.
13. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D et al. (2008). Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86.
14. Kuwano M, Oda Y, Izumi H, Yang S, Uchiumi T, Iwamoto Y et al. (2004). The role of nuclear Y-box binding protein-1 as a global marker of drug resistance. Mol Cancer Ther 3: 1485-1492.
15. Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E et al. (2008). Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68: 8661-8666.
16. Leo C, Horn LC, Einenkel J, Hentschel B, Hockel M. (2007). Tumor hypoxia and expression of c-met in cervical cancer. Gynecol Oncol 104: 181-185.
17. Mani SA, Guo W, Liao M, Eaton E, Ayyanan A, Ahaou AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
18. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T et al. (2000). Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19: 6194-6202.
19. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. (2002). CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 3074-3086.
20. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361.
21. Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M et al. (2008). Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3: 109-118.
22. Sachs M, Brohmann H, Zechner D, Muller T, Hulsken J, Walther I et al. (2000). Essential role of Gab1 for signaling by the c-met receptor in vivo. J Cell Bio 150: 1375-1384.
23. Shadeo A, Lam WL. (2006). Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 8: R9.
24. Shipitsin M, Campbell LL, Argani P, Weremosicz S, Bloushtain-Qimorn N, Yao J et al. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
25. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
26. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439: 993-997.
27. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y et al. (2008). Y-box binding protein-1 (YB-1) serine 102 is a downstream target of p90 ribosomal S6 kinase (RSK) in basal-like breast cancer cells. Breast Cancer Res 10: R99: (e-pub ahead of print).
28. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E et al. (2007). Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9: R61.
29. Sutherland BW, Kucab JE, Wu J, Lee C, Cheang MCU, Yorida E et al. (2005). Akt phosphorylates the Y-box binding protein-1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292.
30. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J et al. (2007). The phosphoinositide-dependent kinase-1 inhibitor 2-amino-n-[4-[5-(2-phenanthrenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide (OSU-03012) prevents Y-box binding protein from inducing epidermal growth factor receptor. Mol Pharm 72: 641-652.
31. Trusolino L, Bertotti A, Comoglio PM. (2001). A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643-654.
32. Trusolino L, Comoglio PM. (2002). Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289-300.
33. van Roeyen CR, Eitner F, Martinkus S, Thieltges SR, Ostendorf T, Bokemeyer D et al. (2005). Y-box protein mediates PDGF-B effects on mesangioproliferative glomerular disease. J Am Soc Nephrol 16: 2985-2996.
34. Welm AL, Kim S, Welm BE, Bishop JM. (2005). MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci USA 102: 4324-4329.
35. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E et al. (2006). Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66: 4872-4879.
36. Yoshida S, Harada T, Mitsunari M, Iwabe T, Sakamoto Y, Tsukihara S et al. (2004). Hepatocyte growth factor/Met system promotes endometrial and endometriotic stromal cell invasion via autocrine and paracrine pathways. J Clin Endocrinol Metab 89: 823-832.
37. Zhao Y, Raouf A, Kent D, Khattra J, Delaney A, Schenerch A et al. (2007). A modified polymerase chain reaction-long serial analysis of gene expression protocol identifies novel therapeutics in human CD34+ bone marrow cells. Stem Cells 25: 1681-1689.